Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme, a Sanofi company, has initiated shipment of Fabrazyme (agalsidase beta) produced at its new plant in Framingham, Massachusetts.
Subscribe to our email newsletter
Fabrazyme is approved for treatment of Fabry disease, an inherited condition that is characterized by excessive accumulation of the lipid GL-3 in various organs and tissues.
Patients in the US will return to full dosing in March 2012 and all new patients are eligible to begin Fabrazyme treatment, the company said.
In Europe the process of moving the most severely affected patients to full dose of Fabrazyme is expected to begin in March 2012.
Genzyme president and CEO David Meeker said the ability to meet the needs of patients in the US is an important first step in restoring unconstrained supply for all patients globally throughout the course of 2012.